A mechanistic and structural investigation of modified derivatives of the diaryltriazine class of NNRTIs targeting HIV-1 reverse transcriptase.
Mislak, A.C., Frey, K.M., Bollini, M., Jorgensen, W.L., Anderson, K.S.(2014) Biochim Biophys Acta 1840: 2203-2211
- PubMed: 24726448 
- DOI: https://doi.org/10.1016/j.bbagen.2014.04.001
- Primary Citation of Related Structures:  
4O44, 4O4G - PubMed Abstract: 
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are vital in treating HIV-1 infection by inhibiting reverse transcriptase (RT). Drug toxicity and resistance drive the need for effective new inhibitors with improved physiochemical properties and potent antiviral activity. Computer-aided and structure-based drug design have guided the addition of solubilizing substituents to the diaryltriazine scaffold. These derivatives have markedly improved solubility and maintain low nanomolar antiviral activity against RT. The molecular and structural basis of inhibition for this series was determined to facilitate future inhibitor development with improved pharmacological profiles.
Organizational Affiliation: 
Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520-8066, USA.